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INTRODUCTION 
Because the rate and extent of drug release from a particular 
pharmaceutical dose form can affect the rate· and extent of pharma-
cologic response (i.e., biological availability), there has developed 
over the p~st twenty or so years, a concern with the production of 
pharmaceutical products that will release drugs more efficiently. To 
this end, researchers have placed increasing emphasis on the disinte-
gration of solid dosage forms, notably compressed tablets. 
Absorption of a drug administered in an intact solid dose form 
~uch as a tablet) follows a fairly well-defined sequence of events, 
and research has focused on examination of the factors affecting the 
several steps in this sequence. Since most drugs are weak electrolytes 
and lipophilic in nature, the time required to cross biological 
membranes is relatively short. However, the rate-limiting step in 
the absorption process for many drugs is dissolution; the drug must 
be in solution in order to. cross the biological membrane. In turn, 
the rate-limiting step in the dissolution of drugs from solid dosage 
forms is commonly disintegration. When a tablet breaks up into many 
smaller particles, the surface area exposed to the solvent media is 
greatly increased. To illustrate this point, if a flat-edged 
(cylindrical) tablet with a thickness of one millimeter and diameter 
of three millimeters breaks up into perfect spheres just small enough 
to pass through the mesh in the U.S.P. Disintegration Apparatus, the 
1 
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increase in surface area would be on the order of 102 . This extremely 
simplistic view of the disintegration process suffers f rom the fact 
that the size of particles often will be smaller than those described 
above, and so the value is greatly underestimated. As surface area 
is increased, dissolution efficiency is also increased. This concept 
is shown schematically in Fig. 1. 
Most of the research on the disintegration of solid dosage forms 
has o.ccurred in recent years, although it is not solely a contemporary 
activity. Indeed, over a century ago a U.S. Patent recommended 
perforation of pills so enhanced penetration of gastric fluid would 
result in faster disintegration (1). In more recent times researchers 
have agreed that tablet disintegration is an extremely important 
parameter in formulating solid dosage forms (2-13), and many substances 
have been tested for their ability to accelerate the disintegration 
process (14-31). A comprehensive list of these agents was compiled 
by Lowenthal (2) . 
To explain the mechanisms by which these disintegrants act, 
several theories have been postulated. Matsumaru (23) proposed that 
the heat of wetting of the disintegrants caused entrapped air in the 
tablet to expand,.and thus produced disintegration. 
Krowczynski, et al. (24), theorized that an increase in the rate of 
disintegration was due to the formation of a larger system of 
capillaries by virtue of smaller particle s izes of starch. 
Jaminet, ~ al. (25) suggested that the disintegration process is 
dependent upon the solubility of the ingredients in the formulation. 
They reported that the rates of disintegration were related to the 
Intact 
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Fig. -Schematic Diagram of the Disintegration Process. 
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rate of liquid penetration into the tablet. Another theory of tablet 
disintegration is concerned with disintegrant swelling. The occurrence 
of swelling of disintegrants has been extensively observed (24-30) . 
It has been postulated that tablets made with a low compressional 
force, giving a high tablet porosity, did not have proper resistance 
to the swelling actions of the disintegrant; the result is a high 
disintegration time. Tablets made with a high compressional force, 
giving a low tablet porosity, did not allow enough fluid to enter the 
tablet and come in contact with the disintegrant; thus the disinte-
gration time was again elevated. Tablets made with a moderate 
compressional force, gave a medium porosity, allowed a sufficient 
amount of fluid to penetrate the tablet, offered an optimum of 
resistance, and resulted in low disintegration times (30,31). There 
have been numerous studies to support this relationship between the 
applied force of compression of the tablets and resultant disinte-
gration time (68-75). 
Although there is some disagreement about which model best 
explains the action of tablet disintegration, it should be realized 
that the mechanism of action of any given disintegrant will probably 
be the resultant of any or all of these mechanisms, or even others 
that have yet to be studied. The disintegration process, by any 
mechanism, follows a specific sequence: tablet disintegration, 
followed by granule disintegration (aggregation) . The process of 
making this sequence more efficient is termed "optimization," which is 
defined as "an effort to achieve the best or more favorable condition 
for a particular situation (64)." 
5 
Optimization of disintegration in pharmaceutical systems is 
controlled by both formulation factors and processing factors. We 
can select the types and/or concentrations of the various ingredients 
in a formulation; and we can modify processing factors such as 
compressional force. 
Although there are published reports where attempts were made to 
optimize disintegration by altering the nature or concentration of 
disintegrant (32-35), or by controlling process variables (3,7,18,36-40, 
48,49), there does not appear to be many published studies where 
attempts were made to optimize disintegration by altering the particle 
size of the disintegrant. Further, to date there have been few 
published studies concerning the use of intra- and extragranular 
disintegrant in pre-compression fo;rmulations. 
Investigators have shown that tablet matrices, for use in 
non-granulated formulations, can be produced by pre-compression (45-47), 
and it therefore seems plausible that this method could be used to 
manufacture excipient systems with intra- and extragranular 
disintegrants. In addition, by varying the process variables used 
in the pre-compression stage, it seems probable that the effects of 
such variables on disintegration may be demonstrated. 
Once a working knowledge of the many process variables and their 
effects on the disintegration process has been obtained for a given 
system, it would be possible to optimize the function of the 
disintegrant in that system. 
The first consideration when choosing a tablet disintegrant should 
be the relative efficiency of commercially available disintegrants in 
( 6 
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the system desired. This should be done by keeping all of the process 
variables constant during tableting, so that the effect of the 
individual disintegrant is the only factor tested. A brief list of 
commercially available disintegrants was compiled (37) and appears in 
Table I. Because these substances, especilly the newer products, 
have been shown to be effective in very low concentrations, they 
should be evaluated in even lower concentrations, in order to discern 
their relative efficiency. 
The selection process should consist of evaluating both the 
physical and chemical (if any) actions of the various disintegrants. 
Availability of these substances and ease of processing should also 
be considered. Once a specific tablet disintegrant has been chosen, 
it would then be advisable to optimize its function within a given 
system. 
There have been numerous investigations into the effect of 
altering the method of disintegrant incorporation on the disintegra-
tion time of tablets (24,51-57). Thus by altering the method of 
incorporation, with all other variables constant, an optimum 
procedure for processing could be obtained. 
It has been generally recognized that disintegration time will 
usually decrease as the disintegrant concentration increases (14-31, 
76-78). However, in at least one study, it has been noticed that 
disintegration time can actually increase with increasing disinte-
grant concentration (79). Although an unusual case, it has been 
generally accepted that very high concentrations of tablet disinte-
grant can cause untoward effects in processing of the tablet (80-82). 
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Table I 
Camnnly Used Tablet Disintegrants * 
Substance 
STARCHES 
MODIFIED STARCHES 
MICR!X:RYSTAILINE 
CEILUIDSES 
CEILUIDSE DERIVATIVES 
(WATER OOWBLE) 
&DIUM ALGINATE 
CLAYS 
ALGINIC ACID 
GUMS 
roLYVINYllOLY-
PYRROLIOONE(PVPP) 
ION EXCHANGE 
RESINS 
SPOCIAL CEILULOSE 
DERIVATIVES 
fypes/Brands 
Corn , maize, potato 
rice. 
Corn starch is rrost 
corrmonly used. 
Sodium carboxymethyl 
starch (Explotab or 
Prinogel) . 
Avicel PH-101 and 
Avicel PH-10'2, 
Avicel RC-591 
Methyl Cellulose, 
Sodium carboxymethyl 
cellulose, 
Hydroxypropyl rrethyl 
cellulose. 
Landalgine 
Veegum 
Guar gum 
Polyplasdone XL 
Kollidon CE5050 
Amberlite IRP-88 
Ac-Di-Sol, CID 
*Adapted fran "Problem Solver", (37), p 
Concentration/Method 
5-1<1% 
t o dry granulation 
1-8% 
5-153 
Wet granulation or 
direct Canpression. 
5-1{1% 
Wet granulation or 
direct canpression. 
2-53 
Wet granulation or 
direct canpression. 
5-1<1% 
Wet granulation or 
direct compression. 
5-1<1% 
Wet granulation or 
direct canpression. 
5-153 
Wet granulation or 
direct canpression. 
0.5-53 
Wet granulation or 
direct canpression. 
0.5-53 
Direct compression. 
0.5-53 
Wet granulation or 
direct compression. 
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It has been suggested that many formulators employ an "overkill" 
approach when formulating tablet disintegrants, thereby allowing 
their product to be more susceptible to the adverse effects of 
disintegrants. 
In addition, although the chemical nature of a disintegrant 
may be known, very few formulators know how the physical nature of 
the disintegrant relates to disintegrant action. The changes that 
occur in drug absorption when particle size is altered has been 
studied (58-63); however, the effect of varying particle size of 
tablet disintegrants has yet to be conclusively delineated (7,24). 
Thus, particle size, as well as other physico-chemical properties of 
the disintegrant should be considered to optimize the disintegrant 
and its function within the pharmaceutical system. Therefore, when 
considering a pharmaceutical system that must disintegrate, the 
effects of processing, procedure, formulation components and the 
disintegrant's chemical and physical properties should be defined 
and evaluated. 
Because the dosage form is expected to conform to certain 
guidelines with respect to the disintegration time, it should be noted 
that any variation in either the disintegration apparatus of the 
procedure used (see methodology section) may cause a variation in 
results of any disintegration test. Thus the testing procedure should 
remain constant throughout the study , in order to assure minimum 
testing error. 
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In addition, the tablet must also conform to tests other than 
disintegration. There are many responses by the tablet to changes 
in the formulation and processing of the dose form. These responses 
and variables responsible for them are shown in Table II. The 
likelihood of arriving at a formulation and procedure that will 
achieve an optimum for all of the response variables is small. The 
formulator may be forced to reach a compromise between all of the 
variables and select a formulation and procedure that may not be best 
for any given response, but that will be the best compromise for all 
responses. This is the basic principle associated with any 
optimization procedure involving more than one variable. 
The first objective of this thesis is to study some of the 
process variables involved when disintegrants are incorporated into 
pre-compression systems, and to determine their effect on the 
disintegration process. Using a chilsonator/mill and varying the 
operating conditions, should make possible the achievement of this 
goal. 
The second objective of the study concerns the selection of an 
appropriate disintegrant by evaluating several tablet disintegrants 
at a low concentration and keeping the process variables constant. 
Finally, the thesis will be concerned with the selection and 
subsequent optimization of one tablet disintegrant. It was thought 
important to study one disintegrant in depth, rather than super-
ficially study many disintegrants in this phase of the thesis. The 
effect of altering the particle size and concentration of the disinte-
grant will be related to parameters such as disintegration and dissolu-
tion times of a number of drugs. 
Ea.1E FORMUI.ATION AND PROCESSING FA~RS AND 
TIIE RESroNSES DEPENDENT ON TIIEM 
FORMUI.ATION VARIABLES RESroNSE VARIABLES 
1. Diluent Ratio 1. Tablet Disintegration 
2. Compressional Force 2. Tablet Hardness 
3. Disintegrant level 3. Drug Dissolution 
4. Binder level 4 . Tablet Friability 
5. Lubricant level 5. Weight Uniformity 
PRCX:ESS CCNSTANI'S 6. Tablet Thickness 
Uniformity 
1. Granulating Conditions 
7. Tablet Porosity 
2. Milling Conditions (Pore Volume) 
3. Drying Conditions 8. Mean Pore Diameter 
4. Dry Blending F,quiprent 9. Tablet Appearance 
and Times of Blending 
10. Mean Granule Diameter 
5. Compressing Machine 
Speed 
* Adapted fran ( 40) , J. B. Schwartz, et al. 
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By examining process variables, relative disintegrating efficiency 
of common disintegrants, and the effect of altering physico-chemical 
properties of a tablet disintegrant, it should then be possible to 
shed some light on the optimization process when applied to tablet 
disintegrants in general. 
( 
EXPERIMENTAL 
A. Material: 
1 
2 
3 
1. Drugs - The drugs used in this study were available commercially. 
Acetylsalicylic Acid (Aspirin) 1 (lot X2729531) 
Ascorbic Acid (Vitamin c) 2 (lot 328956) 
Niacin3 (lot 52080) 
Pyridoxine (Vitamin (lot 6878) 
Riboflavin (Vitamin (lot Pl964) 
2. Disintegrants - The tablet disintegrants used were available 
commercially. The disintegrants with the letters "M.S.D." 
before the lot and code numbers were provided by Merck Sharp 
and Dahme. Those disintegrants with the words "pilot batch" 
in place of the lot numbers were special adaptations of 
commercially available disintegrants, supplied especially 
for experimental purposes and were supplied by the 
manufacturer. 
Ruger Chemical Co., Irvington, New Jersey. 
J. T. Baker Chemical Co., Phillipsburg, New Jersey. 
Merck and Co., Rahway, New Jersey. 
4Nutritional Biochemicals Co., Cleveland, Ohio. 
5Mann Research Laboratories, New York, New York. 
12 
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Ac-Di-Sol 6 (lot s8301) 
Amberlite IRP-88 Resin7 (lot 30665) 
CLD8 (code SR-312) 
Corn Starch, U.S.P. 9 (M.S.D. #77858/27680) 
10 Explotab (lot Cl68) 
13 
Guar Gum9 (M.S.D. #23411/38010) 
Polyvinylpolypyrrolidone, 11 Agent AT-888 (pilot batch) 
Polyvinylpolypyrrolidone, 11 Polyplasdone XL-499 
Special (pilot batch) 
Polyvinylpolypyrrolidone, 11 Polyplasdone XL (lot 1043-2) 
Sta-Rx 1500 Starch12 (lot 2F692) 
3. Excipients - the excipients used in this study were available 
commercially. Those excipients with the letters "M.S .D." 
before the lot and the code numbers were provided by Merck 
Sharp and Do hme • 
6B-1S Corporation, Philadelphia, Pennsylvania. 
7Rohm and Haas Co., Philadelphia, Pennsylvania. 
8Buckeye Corp., Memphis, Tennessee. 
9Merck Sharp and Dahme Research Laboratories, West Point, Pennsylvania. 
10 Edward Mendell Co., Carmel, New York. 
11GAF Corporation, Linden, New Jersey. 
12
staley Starch Co., Decatur, Illinois. 
( 
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Avicel PH-101 13 (lot 1852-3616) 
Avicel PH-102 13 (lot 7701-790) 
14 
Dibasic Calcium Phosphate Dihydrate (Unmilled) 14 
(M.S.D. #84333/24010) 
Dibasic Calcium Phosphate Dihydrate (Milled) 14 
(M.S.D. #84874/21490) 
Lactose (Anhydrous) 14 (M.S.D. #561133-00J03,ND11-45) 
Lactose (Hydrous) 14 (M.S.D. #84333/24010) 
4. Lubricant - The lubricant throughout the study remained 
constant, although the lot numbers were different. 
. 14 15 Magnesium Stearate ' (M.S.D. 1176340/24270) 
(Code N49483) 
5. Equipment - The following equipment was used for the 
analytical procedures, compaction, tableting, and subsequent 
analysis of physical parameters. 
16 Colton Model 216 Rotary Tablet Press 
17 Erweka Hardness Tester, Type TBT (Nr 19306) 
Erweka Tap-Abrasion Tester17 (code lAP) 
13 FMC Corporation, Philadelphia, Pennsylvania. 
14 Merck, Sharp and Dohme Research Labs., West Point, Pennsylvania. 
15 Ruger Chemical Co., Irvington, New Jersey. 
16 Colton Machine Co., Detroit, Michigan. 
17 Erweka Apparatebau, West Germany. 
( 15 18 Hewlett-Packard Desk Top Calculator (Model 10) and 
Plotter (Model 9862A) 
Hot Plate 19 (Model PC-35) 
20 Single Pen Strip Chart Recorder 
Mettler Balance (Model H8) 21 
Mettler Balance (Model PR1200) 21 
22 Alexanderwerk Compactor 
B. Physical Tests: 
The physical tests (excluding powder flow) were performed on the 
tablets produced during the various phases of this study. They 
are as follows: 
1. Weight - The w~ight of each individual tablet was determined 
by dusting each tablet off with a camel hair brush, and placing 
it on an electronic balance. This procedure was repeated for 
ten tablets (in certain cases, it was thought necessary to 
repeat the procedure more than ten times) . The data from the 
tablets was then analyzed for sample mean and Relative 
Standard Deviation (R.S.D.). This procedure is explained 
in part "E" of this section. The R.S.D. value was used as a 
measure of weight variation within a sample of tablets. 
18 Hewlett-Packard Co., Loveland, Colorado. 
19
corning Glass Works, Corning, New York. 
20 . Linear Instrument Co. 
21Mettler Instrument Corporation, Princeton, New Jersey. 
22 Alexanderwerk, Switzerland. 
( 16 
2. Thickness - The thickness of ten tablets was determined by 
first dusting of the surface of the tablet with a brush, and 
then placing it in the jaws of a micrometer. The measurements 
were recorded and analyzed for mean value and R.S.D. as a 
measure of variation. 
3. Hardness - The hardness of ten tablets was determined by 
placing each tablet in an electronic hardness tester (Erweka) 
which recorded the breaking strength of the tablet in kilo-
grams. This procedure was repeated ten times, and the data 
was analyzed for sample mean and R.S.D., as a measure of 
variation. 
4. Friability - This test is a measure of abrasion resistance 
and was determined by first weighing twenty tablets after 
dusting, placing them in a tumbling chamber with plastic 
baffles, and rotating the basket vertically at a fixed rate 
for twenty minutes. The total weight of the twenty tablets 
(or what was left of them) was recorded, after dusting, and 
the percent friability was determined as follows: 
Fr = 100 x Weight (original) - Weight (final) Weight (original) 
5. Disintegration - Tablet disintegration was tested by using 
the U.S.P. apparatus, as described in the National Formulary (10). 
Fig. 2 schematically illustrates how this apparatus is set 
up. The time needed for all the fragments to pass through 
the mesh at the bottom of the test cage was noticed visually, 
and was recorded. A mean value for six tablets was calculated 
and the range of values was also recorded. 
( 
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Fig. 2 -The U.S.P. Disintegration Apparatus, In Use. 
(2)-no disintegration, (1)-in process of disintegration, 
(3)-disintegration completed. 
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6. Dissolution - Drug dissolution was also performed on a U.S.P. 
apparatus, and according to monographs in U.S.P. XIX (97). 
The exact equipment used was the U.S.P. "basket" assembly, and 
5 ml. samples were removed at times of 1/2, 1, 2, 4, 7, 10, 
and 30 minutes, or until 100% dissolution was observed. Plots 
of these readings were made to visually depict the dissolution 
process (see part "E" of this section) . 
C. Analytical Procedures: 
1. Dissolution - When a drug was to be measured for rate and extent 
of dissolution, or content uniformity, a sample of the lot of 
drug to be used was run through a scanning U.V. Spectrophoto-
( meter to determine the A for that particular drug. Once 
max 
this value was determined, the spectrophotometer was set at 
this wavelength, and each sample was analyzed for absorbance 
at this wavelength at various concentrations; the results 
being recorded in a Beer's plot. The drug monograph, as 
it appeared in the U.S.P. XIX, was used as a reference for 
determining the dissolution medium for the test. 
D. Flo'W!Ileter: 
The flowmeter was used to analyze the various flow characteristics 
of the various powders used. The device consisted 0f a stainless-
steel powder hopper suspended over an analog balance, which in 
turn sent output signals to a strip-chart recorder. For 
( 
( 
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practical purposes, the hopper, or funnel was taken from a Stokes 
Model F, single punch tablet press. 
The apparatus was designed, as an extension of work done by 
Duvall and coworkers. They were hampered by the fact that 
convenient analog balances were not available at the time of their 
studies. Jordan and Rhodes applied the concepts outlined by Duvall 
and applied them to modern equipment. The flowmeter used in this 
study was an improvement on the latter design, and is shown in 
Fig. 3. 
The recorder was calibrated such that one kilogram of weight 
caused a pen deflection equal to the entire scale of the chart. 
The chart speed was set at 30 centimeters/minute and remained 
constant throughout the study. 
By removing the glass stop-plate, and allowing the powder to 
fall onto the balance pan, which in turn results in a flowgram, 
or tracing. The flowgrams were then examined for time of powder 
flow by transforming the centimeters covered into seconds. The 
total weight at the top of the scale was read, and the value was 
divided by the number of seconds to give the mass flow rate, in 
grams/second. This is only a mean flow rate, and the rate may 
have changed during the flow process. A measure of this change 
is the linearity value. Since ideal flow has been thought of in 
linear terms, it was felt that by using a linear regression to fit 
the data, and analyzing the least squares correlation 
coefficient (r2) a good index of linearity could be obtained. 
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By altering the r 2 in such a way that all values below 0.8 are 
omitted (as these are unacceptable values) and expanding the 
remaining values to a scale of twenty, a workable linearity index 
is achieved. Thus, the equation for the least squares correlation 
factor conversion is as follows: 
fl = 2 (r - 0.8) x 100 
where: fl = Powder Flow Index 
2 
r = Least Squares Correlation Coefficient 
This evaluation was carried out in three trials, and the powder 
flow characteristics were reported as mean values. Examples of 
how these numbers correspond to the flowgrams can be seen in 
Fig. 4 and 5. 
E. Interpretation of Data: 
1. Physical Tests - The physical tests were run for ten trials 
on each sample set. The data from the sample set was analyzed 
for mean value and Relative Standard Deviation (R.S.D.). A 
digital computer program written in Basic was used to calculate 
these values, using the equation: 
Relative Standard Deviation= R.S.D. s x 100 = -
Where: S = standard deviation of sample 
X = sample mean 
The computer program used appears in Appendix I. 
2. Dissolution - The dissolution samples (five milliliters) were 
not returned to the dissolution bath so that there was a 
( 
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A 
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Avg. 
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Flow 
~Se..£ Yneari!z 
196 19,5 
196 18.3 
196 18.6 
196 18.8 
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Flow 
Run (g/sec) Linearity 
A 18.5 13.6 
B 19. 3 12.4 
c 20.0 8.8 
.. 
Avg. 19 . 3 11.6 
<! TIME 
Fig. - Three Nonlinear Flowgraph Tracings 
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certain amount of drug being lost in each sample. This drug 
loss reflects on subsequent samples and thus introduces an 
error in procedure. This error was corrected by using a 
digital computer program utilizing the following equations 
to determine the amount of drug in the five milliliter sample: 
Cone = A - b 
m 
Where: A = absorbance 
m = slope of Beer's Plot 
b = intercept of Beer's Plot 
The computer program appears in Appendix II. 
( 
METHODOLOGY 
A. Validation of Compactor: 
Milled dibasic calcium phosphate dihydrate, hydrous lactose, and a 
1:1 mixture of these two excipients were the three systems chosen for 
the validation procedure. Each system was run through the compactor 
(see Fig. 6), while the various machine settings were altered during 
the granulation process. Two speeds of the compression rollers were 
possible, and these were designated as "slow" and "fast." The auger 
screw speed was continuously variable from settings of "O!' to "9" 
and four speeds were chosen: #1 (7 r.p.m.), #3 (15 r.p.m.), #6 
(30 r.p.m.) and 119 (45 r.p·.m.). The compactor pressure was also 
continuously variable from 0-100 atmospheres (ATM) and the following 
compaction pressures were chosen: 30 ATM, 50 ATM, and 70 ATM. In 
each run, there was a #16 screen mesh used for the mill portion of 
the machine. 
By varying the roller speed, the dwell time, or the time that the 
powder was exposed to pressure was varied. By altering the auger 
screw speed, the amount of powder pushed between the rollers was also 
varied. There were certain conditions that were unfavorable, and 
caused a great deal of machine strain that was heard and seen. 
Because of this, any run that was not to be considered free of machine 
strain, was rejected and not included in the test study. 
25 
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Mechanics of the 
Alexandeiwerk Compactor 
The speed of the auger screw (A) can be 
varied. This screw forces the powder 
between the rollers (B) which can be 
adjusted to vary the compaction pressure. 
The powder leaves the rollers as a 
canpressed "band." This band falls to 
a set of milling blades (C) which gradually 
break down the band and force the particles 
through a wire mesh (D) . The resulting 
particles are larger in diameter 
than the original powder particles and 
this results in a " dry granulation. " 
·~\\\\~· 
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By varying all of the previously mentioned variables, it was 
possible to provide for 24 theoretical granulation conditions. The 
granulations were then subjected to a sieve analysis and bulk/tap 
density measurements. The sieve analysis and bulk/tap density measure-
ments were also taken on the powders before compaction, and served as 
a control. 
The data associated with this part of the study appears in 
Tables III-IX. 
B. Selection of Compacted Matrix: 
The granulations produced in part A of this section were lubricated 
by mixing in magnesium stearate, in a 0.5% (W/W) concentration, in a 
twin-shell blender for fifteen minutes. The lubricant was passed 
through a #60 mesh bolting cloth before addition to the granulation 
as to inhibit agglomeration of magnesium stearate during the mixing 
process. Various physical mixtures of the already compacted matrices 
were prepared. The calcium phosphate and lactose were mixed in 25:75, 
50:50 and 75:25 ratios. Using an instrumented Stokes Model F single 
punch press, the applied pressure was kept fairly constant at 
3700 pounds. The resulting tablets were then tested for weight, 
thickness, hardness, and disintegration time by procedures outlined 
previously. The data resulting from these tests appears in Table X. 
C. Starch U.S.P. Disintegration of the Compacted Materials: 
Based on the disintegration results in part B of this section, 
calcium phosphate and lactose in a 75:25 ratio was chosen as the test 
( 
I 
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system. Mixtures for this segment of the study were prepared in three 
different ways. Dibasic calcium phosphate dihydrate and hydrous 
lactose were compacted under conditions determined in part A of this 
section: SO ATM pressure, slow roller speed, and auger screw speed 
#3. They were mixed together in a 75:25 ratio and corn starch U.S.P. 
was added in increasing amounts (1/2%, 1%, 2%, 5% and 10%, with a 
control system with no disintegrant) by mixing the ingredients in a 
twin shell blender for five minutes. 
The same lots of calcium phosphate and lactose were then mixed 
in a 75:25 ratio . again, but this time were compacted together. Again 
the same lot of corn starch was added in increasing amounts and mixed 
in the same manner . 
For the third test system, calcium phosphate and lactose were 
mixed in a 75:25 ratio with the various amounts of starch being added 
before compaction. This latter system represents the only system where 
starch was compacted. As with all of the previous test systems, the 
granulations were lubricated with 0.5% magnesium stearate, added after 
compaction. 
The three systems were then tableted on an instrumented Stokes 
Model F, single punch press. An effort was made to keep the applie~ 
compressional force constant at 3700 pounds. The tablets produced 
were tested for weight, thickness, hardness,and disintegration time, 
and the data appears in Tables XI-XIII. 
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D. Effects of Low Levels of Disintegrants: 
After testing the effects of process variables on the disintegration 
process, it was of interest to examine the effects of low levels of 
various disintegrants in one of the systems chosen from part B of this 
section. 
Unmilled calcium phosphate and lactose (anhydrous) were mixed in a 
75:25 ratio in a twin-shell blender, for fifteen minutes. This 
mixture was then used as the excipient system throughout this part of 
the study, and served as the control system when no disintegrant was 
used. Eight tablet disintegrants were chosen: corn starch, U.S.P.; 
Amberlite (IRP-88 (an ion-exchange resin); CLD (an anionic polymer of 
cellulose); Explotab (carboxymethyl starch derivative); Ac-Di-Sol 
, 
( (modified cellulose gum); Sta-Rx 1500 Starch (pre-gelatinized starch); 
Polyplasdone XL (cross-linked polyvinylpolypyrrolidone), and guar gum. 
These disintegrants were added to the system described above in 
co~centrations of 0.25%, 0.5%, 1% and 2% (w/w) by mixing the appropriate 
amount of disintegrant with the excipient system and magnesium stearate 
at a 0.5% level, for fifteen minutes in a twin-shell blender. 
Each disintegrant/excipient system and control was then tableted 
using the instrumented press described earlier. The applied compression 
force was kept constant at 3700 pounds for each formulation. The 
resulting tablets were then tested for weight, thickness, hardness, 
and disintegration. 
In addition to the tableting studies, each formulation was tested 
for its flow properties. Each disintegrant was added to the excipient 
( 
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system in concentrations of 0.25%, 0.5%, 1% and 2% (w/w) with a 
control system. One kilogram of each system was then run through the 
recording powder flowmeter, described earlier. Each system was 
evaluated for mass flow and deviation from linear flow. 
The tablet and flow data for each disintegrant is listed in 
Tables XIV-XX!. 
E. Optimization of P.V.P.P. as a Disintegrant: 
Since the effects of excipient system and concentration on 
disintegrant activity was examined in sections B, C, and D, it was 
felt that optimization of the disintegrant itself should be attempted. 
One of the disintegrants studied in part D of this section, 
polyvinylpolypyrrolidone (P.V.P.P.) was available in 3 particle size 
ranges: 0-15 microns (Grade "A"), 50-100 microns (Grade "B"), and 
50-300 microns (Grade "C") . 
Using an effective disintegrant concentration from part D of 
this section (2%), the three various grades of P. V.P.P. were combined 
by mixing in a stainless-steel twin shell blender with three different 
matrices of varying flow properties. The recording powder flowmeter 
was used to evaluate the effects of particle size of disintegrant on 
powder flow. 
Using a Colton rotary tablet press at a speed of approximately 
600 tablets/minute, the various grades of P.V.P.P . and excipients were 
tableted according to the following formulation: 
( 
( 
Aspirin 
P.V.P.P. 
(A,B,or C) 
Talc 
Excipient 
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30.0% (w/w) 
2.0% (w/w) 
0.5% (w/w) 
q.s. 
100.0% 
Tablet weight, hardness, riability, thickness and disintegration 
tests were carried out by previously described methods. 
Dissolution of aspirin :in the formulation was carried out in a 
medium of 0.1 N HCl at 37°C. A scanning ultraviolet (U.V.) spectra-
photometer was used to determine the A of the given lot of aspirin, 
max 
and all dissolution was carried out at this wavelength. The data 
represented :in this section can be seen in Tables XXII-XXV and 
Fig. 9-11. 
From examination of the above data, one particle size (Grade C) 
was chosen. A concentration profile of P.V.P.P., grade C was obtained 
by incorporating concentrations of P.V.P.P. at 1, 2, 5, 10 and 20% 
(w/w) with a control, into the excipient system by mixing for 15 
minutes in a stainless-steel tw:in shell blender. Calcium phosphate 
(Emcompress) was chosen for its resistance to changes in flow. Using 
the recording powder flowmeter described earlier, the powder systems 
were analyzed for mass flow and deviation from linear flow. This 
data appears in Table XXVI. 
The disintegrant was then added in the same concentrations to a 
multivitamin formulation by mixing all ingredients for fifteen 
minutes in a stainless-steel twin shell blender. The formulation 
[ 
was as follows: 
Riboflavin (B 2) 
Pyridoxin (B 6) 
Niacin 
Ascorbic Acid (C) 
Mag. Stearate 
P.V.P.P. (grade C) 
Emcompress 
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0.7% (w/w) 
1.0% (w/w) 
7.0% 
20.0% 
0.5% 
X.X% 
q.s. 
100 % 
The formulation was then tableted on a Colton rotary tablet press 
at a speed of approximately 600 tablets/minute. The resulting tablets 
were evaluated for weight, thickness, hardness, friability and dis-
integration by the previously described procedures, and the data is 
represented g~aphically in Fig. 12-17. 
Once a particle size of the disintegrant, compatibility of matrix/ 
excipient, and an effective concentration of disintegrant were found, 
a formulation considering all of variables was developed: 
Pyr~doxin (B6) 
P.V.P.P. (grade C) 
Mag. Stearate 
Emcompress 
5.0% (w/w) 
2.0% 
0.5% 
q.s. 
100 % 
The ingredients were mixed for fifteen minutes in a stainless-steel 
twin shell blender and subsequently tableted using a Colton rotary 
tablet press. Again, the approximate speed of the press was 
( 33 
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600 tablets/minute. The tablets were tested for weight, thickness, 
hardness, friability, and disintegration, by the previously described 
methods. The data is listed in Table Y.XVII. 
Dissolution was carried out in 0.1 N HCl at 37°C. A scanning 
ultraviolet (U.V.) spectrophotometer was used to determine the A 
max 
for the given lot of pyridoxine and three subsequent dissolutions were 
run at this wavelength. These dissolution curves can be seen in Fig. 19. 
Content uniformity was performed by placing a tablet in a vial, 
and allowing it to fully dissolve in the medium over a period of 
30 minutes. After suitable dilution, the absorbance of the solution 
was measured at the A previously determined for pyridoxine. This 
max 
procedure was repeated for thirty tablets. 
( 
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RESULTS AND DISCUSSION 
Because it was a new experimental device, the compactor used for 
producing the intra and extra-granular disintegrant systems was 
calibrated. The various excipients were tested for density and 
particle size distribution by sieve analysis. The results are listed 
· in Table III. The densities and particle size distributions of the 
excipients under the various experimental conditions are compiled 
in Tables IV-IX. These values became the standards for comparison 
of subsequent work. 
A. Compacted Dibasic Calcium Phosphate (Tables IV, V): 
For dibasic calcium phosphate, compaction at any machine setting 
led to particle sizes larger than the standard. As the auger screw 
speed increased, there was a tendency for the particle size to increase 
to a point, and then drop slightly. This effect was observed at both 
slow and fast roller speeds. However, this drop in particle size was 
not nearly so low as that for the lowest screw setting value. As the 
auger screw speed increased, the amount of po-wder forced between the 
rollers increased, and a larger particle was produced as the result of 
a thicker, denser band. However, when the highest screw speed was 
used, the resulting particle size decreased slightly, possibly because 
when large particles are milled, fracture takes place. This fracture 
can tend to lower the overall particle size because of breakage and 
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CONTROL DATA: DENSITY & SEIVE ANALYSIS OF EXCIPIENTS PRIOR 
TO COMPACTION. 
Excipients: Calcium Phosphate Lactose l : l Calcium Phosphate * 
Lactose 
Density: 
Bulk- 0.704 0.633 0.759 
Tapped- 1.111 0.909 1.111 
·seive Analysis: 
% Left on #30 Mesh 0.0 0.0 0.0 
% Left on #50 Mesh 0.2 o.o Trace (0.0) 
% Left on #100 Mesh 7.2 4.3 5.8 
% Left on #200 Mesh 32.3 49.6 25.8 
% Left on #325 Mesh 53.2 7.4 30.5 
• % Left on Base 7.1 38.7 37.9 
w 
U1 
Geometric Mean 
Diameter (in microns) 77.5 71.6 64.0 
* Mixed in a stainless-steel twin shell blender for fifteen minutes 
.--, .----.._ 
CALCIUM PHOSPHATE SLOW ROLLER COMPACTOR PROFILE 
Pressurea: 30 ATM Pressure 30 ATM Pressure 30 ATM Pressure 
b Screw Speed : 1 3 6 9 1 3 6 9 1 3 6 9 
Density (gm/ml): 
Bulk- 0.926 0.962 u u 0.909 0.980 0.961 0.980 0.962 1.000 u u 
Tapped- 1. 25 1. 35 u· u 1. 35 1. 39 1. 39 1. 02 1. 39 1. 39 u u 
Seive Analysis c 
#30 45.1 28.7 u u 25.5 38.4 40.9 35.3 35.5 41.1 u u 
#50 16.2 15.8 u u 15.4 16.5 16.7 16.2 19.0 20.1 u u 
#100 7.0 8.2 u u 6.8 6.9 8.0 8.7 8.9 8.9 u u 
#200 12.6 29.3 u u 34.8 18.2 18.1 23.5 25.9 11. 7 u u 
#325 16.4 13.3 u u 15.0 16.0 12.7 13.7 9.7 15.4 u u 
Base 2.6 4.2 u u 2.5 4.0 3.1 2.2 2.5 2.0 u u 
Geometric Mean 
Diameterd: 327.7 234.8 u u 217.3 282.1 311.3 277.7 290.8 329.8 u u 
a. Roller pressure ~n atmospheres (ATM) 
b. Auger screw speed ~see Methodology) w 
°' 
c. Percent retained on seive screen 
d. In microns 
...--.. 
CALCIUM PHOSPHATE FAST ROLLER COMPACTOR PROFifuE 
Pressure a 30 ATM Pressure 30 ATM Pressure 30 ATM Pressure 
b Screw Speed : 1 3 6 9 1 3 6 9 1 3 6 9 
Density (gm/ml): 
Bulk- 0.769 0.926 0.926 0.877 0.769 0.877 0.943 0.909 0.746 0.893 u u 
Tapped- 1.16 1. 39 1.39 1. 35 1. 32 1. 37 1. 39 1. 35 1.19 1.35 u u 
Seive Analysis c 
#30 6.5 24.4 27.4 18 . 7 6.3 28.8 26.6 23.9 9.6 22.5 u u 
#50 7.6 17.5 17.9 16.5 4.2 17.8 16.7 15.7 7.7 16.3 u u 
#100 21. 5 8.8 9.8 10.7 14.5 6.9 8.2 5.9 13.0 11. 9 u u 
#200 52.1 35.2 33.7 42.9 57.0 32.2 33 . 5 46.8 57.8 35.0 u u 
#325 10.4 11. 0 8.3 9.0 16.7 10.6 12.8 6.1 9.1 11. 7 u u 
Base 1. 7 2.7 2 . 1 1. 8 0.7 3.2 2.1 1.4 2.6 2.6 u u 
Geometric Mean 
Diameterd: 151. 3 227.6 252.1 206.5 133.1 246.7 233.0 225.0 152.1 218.5 u u 
a. Roller pr~ssure in atmospheres (ATM) w 
-...J 
b. Auger screw speed (see Methodology) 
c. Percent retained on seive screen 
d. In microns 
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production of "fines" or small bits and pieces of granule. This 
break-up may have occurred only at the highest screw speed setting 
when the extreme rate of speed exerted undue force on the powder 
between the rollers. 
When set at screw speeds #6 a..~d #9, the compactor was unable to 
compact at 70 atmosphers (ATM) pressure at either roller speed. This 
problem can easily be explained by the presence of too much powder under 
too great a pressure, at too great a speed. 
The compactor would also not run at 30 ATM, slow roller, and 
screw speeds #6 and #9. This problem may have been caused by the fact 
that the dwell time for the powder is greatest on a slow roller, and 
at 30 ATM pressure, more pow4er may have been forced between the 
rollers. At the fast auger screw speeds, the flow of powder to the 
rollers may have been too fast; however, this condition was not seen 
at SO ATM or at 30 ATM with the fast roller speed. 
B. Compacted Lactose SOM (Tables VI, VII): 
Similar to calcium phosphate, particle size increased when lactose 
was run through the compactor at any given machine setting. Particle 
size generally tended to increase up to the #6 screw speed setting, 
and decrease slightly under the #9 screw speed setting. This ef f ect 
was also seen with the compacted calcium phosphate, and the mechanism 
was probably the same for both exc i pients. 
The compactor was unable to run at many of the lower screw speeds 
f or most pressures. This observation was the reverse of that seen f or 
the calcium phosphate and could possibly be explained by the small 
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LACTOSE SLOW ROLLER COMPACTOR PROFILE 
Pressurea: 30 ATM Pressure 30 ATM Pressure 30 ATM Pressure 
b Screw Speed : 1 3 6 9 1 3 6 9 1 3 6 9 
Density (gm/ml): 
Bulk- 0.758 u 0.685 0.685 u 0.704 0.675 0.675 u u 0.685 0.685 
Tapped- 1.111 u 1.042 0.961 u 0.926 0.926 0.943 u u 0.943 0.943 
Seive Analysis c 
#30 21.1 u 35.6 30.5 u 36.9 32.8 33.3 u u 35.9 38.7 
#50 11.0 u 19.0 19.5 u 21. 8 22.2 21. 6 u u 23.0 23 . 1 
#100 6.3 u 11. 7 11.0 u 7.1 10.9 8.6 u u 8.4 9.4 
#200 26.1 u 31.1 21.1 u 15.1 30.5 16.1 u u 17.8 18.5 
#325 14.9 u 2.0 16.1 u 16.6 2.9 17.6 u u 13.4 9.9 
Base 20.5 u 0.2 1.5 u 2.6 0.6 3.0 u u 1. 3 0.6 
Geometric Mean 
Diameterd: 152.6 u 326.1 264.4 u 297.8 315.6 275.2 u u 310.7 340.7 
l>J 
a. Roller pressure in atmospheres (ATM) 
"' 
b. Auger screw speed (see Methodology) 
c. Percent retained on seive screen 
d. In microns 
.--
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LACTOSE FAST ROLLER COMPACTOR PROFILE 
Pressure a 30 ATM Pressure 30 ATM Pressure 30 ATM Pressure 
b Screw Speed : 1 3 6 9 1 3 6 9 1 3 6 9 
Density (gm/ml): 
Bulk- u u 0.684 0.67:5 0.649 u 0.694 0.666 0 . 666 u u 0.675 
Tapped- u u 0.925 0.925 0.943 u 0.943 0.943 0.943 u u 0.943 
Seive Analysis c 
#30 u u 40.2 36.6 11. 3 u 36.4 27.4 11. 6 u u 32.5 
#50 u u 21.2 18.4 7.8 u 22.6 22 . 9 8.4 u u 24.1 
#100 u u 8.7 10.7 7.9 u 6.2 11. 6 6.5 u u 10.5 
#200 u u 27.7 22.5 49.8 u 17.6 33.3 49 . 5 u u 21. 9 
#325 u u 1. 8 10.5 21. 4 u 15.7 5.0 21. 4 u u 10.5 
Base u u 0.5 1.5 2.1 u 1. 3 0.6 2.9 u u 1.1 
Geometric Mean 
Diameterd: u u 359.6 304.3 141. 5 u 303.1 280.1 140.9 u u 302.1 
-
a. Roller pressure in atmospheres (ATM) ~ 0 
b. Auger screw speed (see Methodology) 
c. Percent retained on seive screen 
d. In microns 
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density difference and the larger amount of fine particles in the 
lactose which might either require more powder to be compressed at 
one time or might not be as compressible as the calcium phosphate. 
C. Compacted Calcium Phosphate/Lactose, 1:1 (Tables VIII, IX): 
When calcium phosphate and lactose, in a 1:1 ratio were compacted 
together, any machine setting increased particle size. Since this 
effect was seen for each substance alone, this result was expected. 
Again, the particle size decreased slightly from the #6 to #9 screw 
speeds. However, the trend to increase particle size at the lower 
screw speed settings, although evident, was much more variable than 
when either excipient was run by itself. In fact, at 30 ATM pressure, 
there was little change in particle size when auger screw speed varied. 
Since the compactor was able to run at all settings for the mixture 
of excipients, the complete set of data was subjected to a step-wise 
regression, with the following variables: 
xl = Auger Screw Speed 
x2 = Roller Pressure 
x3 = Roller Speed 
y = Geometric Mean Diameter 
X0 = Control Geometric Mean Diameter 
The results showed that the most important factor in the increase 
in particle size was the roller speed. The next most significant factor 
was the auger screw speed, and the least significant factor was the 
roller pressure. The regression was performed using a statistical 
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CALCIUM PHOSPHATE/LACTOSE (1:1) SLOW ROLLER COMPACTOR PROFILE 
Pressure a 30 ATM Pressure 30 ATM Pressure 30 ATM Pressure 
b Screw Speed : 1 3 6 9 1 3 6 9 1 3 6 9 
Density (gm/ml): 
Bulk- 0.925 0.925 0.925 0.862 0.806 0.925 0.925 0.862 0.833 0.862 0.877 0.892 
Tapped- 1.136 1.136 1.162 1.162 1.063 1.190 1.136 1.136 1.111 1.136 1.162 1.162 
Seive Analysisc: 
#30 34.5 35.7 31.1 34.6 36.8 30.4 36.7 38.4 40.7 34.2 40.6 44.0 
#50 18.2 17.8 20.6 19.3 18.5 23.1 20.6 23.1 15.7 22.4 22.5 19.1 
#100 9.1 10.2 10.6 8.9 4.6 10.4 7.7 9.3 7.5 8.7 8.6 7.0 
#200 25.1 16.2 24.5 14.3 20.5 17.1 12.6 13.7 15.4 14.8 12.7 11. 4 
#325 11. 3 15.9 12.5 19.3 8.0 14.4 18.0 13.8 17 . 6 12.0 12.7 9.4 
Base 2.0 4.3 0.5 3.2 11. 9 4.8 4.1 1. 3 2.9 7.9 3 . 1 8.7 
Geometric Mean 
Diamete r d 284.3 276.9 280.3 272.4 265.6 268.1 286.6 329.7 295.1 279.1 334.1 326.9 
a. Roller pressure in atmospheres (ATM) 
""' N 
b. Auger screw speed (see Methodology) 
c. Percent retained on seive screen 
d. In microns 
,,,--.. 
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CALCIUM PHOSPHATE/LACTOSE (1:1) FAST ROLLER COMPACTOR PROFILE 
Pressure a 30 ATM Pressure 30 ATM Pressure 30 ATM Pressure 
b Screw Speed : 1 3 6 9 1 3 6 9 1 3 6 9 
Density (gm/ml): 
Bulk- 0.833 0.847 0.833 0.862 0.781 0.833 0.862 0.833 0.769 0.833 0.833 0.833 
Tapped- 1.086 1.136 1.136 1.162 1.136 1.136 1.136 1.136 1.111 1.111 1.111 1.111 
Seive Analysisc: 
#30 37.0 35.2 33.7 36.7 13.1 33.5 31. 5 29.7 4.5 33.2 36.6 28.4 
#50 19.2 20.7 16.8 18.5 5.8 17.8 18.1 15.8 3.3 18.7 16.7 15.9 
#100 8.9 11. 4 8.2 9.4 9.2 8.8 12. 7 7.5 4.3 9.7 5.7 8.8 
#200 16.3 22.8 20.1 21.0 48.8 20.7 16.2 33.5 53.5 17.9 16.8 19.4 
#325 15.4 10.4 16.9 7.8 19.8 12 . 5 17.8 10.1 26.0 15.5 12.8 24.9 
Base 3.5 0.4 4.3 6.1 3.8 6.2 3.3 4.0 8.1 5.0 11. 5 2.8 
Geometric Mean 
n· d 1ameter : 290.2 308.3 256.9 294.6 142.8 263.4 260.1 242.0 102.3 264.0 253.7 220.2 
a. Roller pressure in atmospheres (ATM) .i::-
w 
b. Auger screw speed (see Methodology) 
c. Percent retained on seive screen 
d. In microns 
l 
program titled "SAS." The actual results of the regression are 
tabulated in Appendix III. 
D. Tablet Characteristics of Compacted Materials (Table X): 
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After compaction the systems under study were lubricated and 
tableted either as a mixture of as a single entity on a Stokes Model F, 
single punch press which was computer-instrumented. The instrumentation 
consisted of pressure-sensitive transducers placed at the heads of the 
machine punches. The output from these transducers was relayed to a 
digital computer which monitored both applied and transmitted forces. 
In this way, it was easy to keep the applied force constant during 
tableting. 
During the compressing operation, the weight adjustment setting 
on the tablet press was maintained at a constant level; thus the 
volume of powder fill remained constant. It should be noted therefore, 
that the variation in tablet weights, as seen in Table X, reflects 
the change in density of the six powders. 
It should be noted further that when the applied pressures for 
the tablet compression are similar (3600-4000 lbs.), the mean hardness 
values for the several excipients and mixtures were likewise similar 
(7-9 kg.). Hardness did not change significantly with the 
various excipient systems, although in the physical mixtures of 
compacted excipients, hardn~ss did appear to rise slightly with 
increasing calcium phosphate concentration. 
~  
PHYSICAL PROPERTIES OF TABLETS MADE FROM COMPACTED FORMULATIONS 
(CALCIUM PHOSPHATE, LACTOSE) 
Formulation 
Applied 
Pressure(lbs.) 
R.S.D. 
Mean Weight (mg . ) 
R.S.D. 
Mean Thickness 
(mm.) 
R.S.D. 
cal. phos. 
lactose 
1 : 1* 
4031 
10.6 
275 
0.9 
3.50 
0.5 
Mean Hardness (kg.) 8.2 
Range 7.5-9.0 
Mean Disintegration 
Time (min.) 33.0 
Range 30.8-35.8 
calcium 
phosphate 
3613 
15.2 
285 
3.6 
3.09 
1. 9 
8.9 
4. 3-11. 3 
120 
120 
lactose 
3964 
6.8 
236 
1.4 
3.45 
0.7 
8.7 
6.0-11.3 
1. 3 
1.0-1.6 ) 
cal. phos. 
lactose 
25:75 
3694 
9.6 
258 
1.4 
3.54 
0.6 
6.7 
5.3-8.8 
4.6 
3.1-6.3 
cal. phos. 
lactose 
50 : 50 
3907 
8.1 
269 
2.2 
3 . 39 
1. 7 
7.9 
5.8-10.3 
27.5 
23.3-33 . 8 
.-.... 
cal, phos. 
lactose 
75 : 25 
3890 
8.5 
278 
1.9 
3.25 
0.7 
8.6 
6. 5-11. 3 
93 . 0 
70-120 
* The 1:1 mixture was mixed before compaction while the last three (25:75, 50 : 50, 75 : 25) 
were physically mixed after compaction of the individual excipients. 
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100 
Fig. Change in Disintegration Time as Percent Lactose in 
Calcium Phosphate Dihydrate Increases in the Compacted 
System. ( 0 -Measured time , ingredients compacted separately, 
0-Measured time , ingredients compacted together, 
.t.-Value is in excess of plot, testing was discontinued) 
( 
( 
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Under these pressure conditions, the calcium phosphate tablets 
failed to disintegrate within two hours, while the lactose tablets 
disintegrated within two minutes , However, the lactose systems 
may have undergone more of a salvation phenomenon in the aqueous 
disintegration medium, rather than ordinary disintegration. For 
the 1:1 mixture, the disintegration time was approximately 
one-half hour and the properties lent by the water-soluble component, 
lactose, were evident in the results for the mixture. It was 
also observed that as the lactose concentration increased, the 
disintegration time decreased. This relationship is illustrated 
in Fig. 8. 
By mixing calcium phosphate and lactose before compactions, 
disintegration time was not greatly altered from that of the 
physical mixtures after compaction (see columns 1 and 5 of 
Table X) . 
The effect of a disintegrant, corn starch, on the disintegration 
.of one of these systems then became of interest. In order to 
find a system that would yield a noticeable change in disintegration 
time, a system with a long disintegration time was sought. The 
calcium phosphate/lactose (75-:25) system was chosen. 
E. Starch in a Mixture of Compacted Excipients (Table XI): 
Tableting of the systems where calcium phosphate and lactose 
were compacted separately and the starch was added later, was 
( 48 
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carried out under constant applied pressure, as before. The 
hardness values for this series of tablets fell within a range 
of 7.5-10 kilograms. As expected, the disintegration time 
decreased as starch concentration increased. 
The effects of corn starch first became evident at a low 
concentration of one-half percent (w/w); and at this level, 
disintegration time was reduced by 50%. If a maximum target 
disintegration time can be set at 30 minutes or less, one 
percent starch would seem to be effective. A two percent 
concentration yielded a disintegration time of two to five 
m·inutes. 
These were surprisingly effective lower concentrations 
of corn starch than have been reported by conventional litera-
ture sources (65-67). Although these sources have stated that 
concentrations of five to twenty percent (w/w) were effective, 
concentrations above five percent in this system have yielded 
extremely fast disintegration rate. These may have been too 
fast to be considered optimum for this system and may comprise 
an "overkill" approach to tablet disintegration. 
It should also be noted that there did not seem to be 
a significant change in hardness as the starch concentration 
increased. 
* PHYSICAL PROPERTIES OF TABLETS MADE FROM FORMULATIONS WITH 
Applied Force 
(lbs. ) 
R.S.D. 
Mean Weight 
(mg.) 
R.S.D. 
Mean Thickness 
(mm.) 
R.S.D. 
Mean Hardness 
(kg. ) 
Range 
Mean Disintegration 
Time (min.) 
Range 
0% 
3890 
8.5 
278 
1. 9 
3.25 
0.7 
8.6 
6. 5-11. 3 
93 
70-120 
INCREASING AMOUNTS OF STARCH ADDED 
!% 
4608 
13.3 
284 
2.1 
3.19 
1.6 
9.8 
6.0-12.5 
55.3 
25. 3-77 .. 9 
Starch Concentration (w/w) 
1% 2% 
3973 
13.5 
271 
2.2 
3.09 
1.5 
7.6 
5.5-11.0 
23.6 
21. 6-26 .1 
3266 
12.2 
276 
2.3 
3.17 
1. 0 
6 . 3 
4.5-8.5 
0.8 
0.5-0.9 
5% 
3637 
11. 9 
271 
1. 2 
3.13 
0 . 9 
7.7 
6 . 0-10.0 
0 . 1 
0 . 1-0 . 2 
* Calcium phosphate/lactose, 75:25, compacted separately, then starch added 
10% 
3046 
19.8 
256 
5.5 
3 . 07 
2.7 
6.6 
1.5-9.5 
0.1 
0.1-0.2 
~ 
l.O 
I 
( 
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F. Starch in Compacted Mixture of Excipients (Table XII): 
In the second system, where the calcium phosphate and the lactose 
were compacted together with the starch being added later, it was 
obvious that adequate disintegration did not obtain at a concentration 
of two percent, but was reached at five percent of starch in the 
formulation. 
The control system, when compared to the first control system 
(separately compacted excipients) gave a disintegration time in excess 
of two hours. No decrease in disintegration time was observed for 
starch added in concentrations of one-half, one and two percent. 
A disintegrant level of five percent resulted in a disintegration 
time range of one to four minutes. A value between two and five 
percent may have " produced intermediate values. 
This phenomenon may have resulted from the fact that lactose is 
the water soluble excipient in this system, and may have been "hidden" 
within the calcium phosphate, resulting in an excipient with properties 
closely related to the calcium phosphate (high disintegration times). 
Again, there were only slight changes in hardness as starch 
concentration increased. 
G. Starch Compacted in with the Mixture of Excipients (Table XIII): 
In the third test system, where the two excipients and the starch 
were compacted tog~ther, disintegration under 30 minutes was again 
achieved by using only one percent starch in the formulation. An 
average disintegration time of three minutes was also achieved with 
two percent starch in the formulation. 
.-... 
......, 
* PHYSICAL PROPERTIES OF TABLETS MADE FROM FORMULATIONS WITH 
INCREASING AMOUNTS OF STA~CH ADDED 
Starch Concentration (w/w) 
0% ~% 1% 2% 5% 10% 
Applied Force 3574 3450 3786 3320 3711 3474 (lbs. ) 
R.S.D. 9.7 10.7 15.6 8.0 14.4 12.3 
Mean Weight 274 273 270 274 270 268 (mg.) 
R.S.D. 2.6 2.1 2.8 1. 4 1. 9 1. 4 
Mean Thickness 3.1 3.1 3.1 3.2 3.1 3 . 2 (mm.) 
R.S.D. 1.4 0.9 1. 3 0.7 1.1 1.2 
Mean Hardness 7.4 5.8 7.1 4.9 6.7 5.4 (kg.) 
Range 5. 5-11. 5 4.5-9.0 4.0-12.5 4.0-6.0 5.0-11.0 4.5-7.5 
Mean Disintegration 
Time (min. ) 120+ 120+ 120+ 120+ 2.2 0.2 
Range - - - - 0.8-3.9 0.2-0.3 
\.J1 
* Calcium phosphate/lactose, 75 : 25 compacted together, then starch added ...... 
b_ur_r~ 
.~ 
PHYSICAL PROPERTIES OF TABLETS MADE FROM FORMULATIONS* WITH 
INCREASING AMOUNTS OF STARCH ADDED 
Starch Concentration (w/w) 
0% ~% 1% 2% 5% 10% 
Applied Force 3574 3722 3835 3345 3906 3676 (lbs. ) 
R.S.D. 9.7 7.8 8.8 9.6 13.9 12.1 
Mean Weight 274 272 276 274 270 274 (mg.) 
R.S .. D. 2.6 3.0 1. 6 1. 9 1. 9 1. 7 
Mean Thickness 3.11 3.12 3.14 3.18 3.18 3.19 (mm.) 
R.S.D. 1.4 1.6 1. 0 1.1 1. 4 1.0 
Mean Hardness 7.4 6.1 6.3 5.5 7.9 7.7 (kg.) 
Range 5. 5-11. 5 3.5-9.0 5.0-8.0 4.0-6.5 5. 5-11. 0 5. 5-11. 0 
Mean Disintegration 
Time (min. ) 120+ 120+ 20.5 2.7 0.3 0.2 
Range - - 13.?.-27.8 2.1-3.6 0.3-0.4 0.2-0.3 
*Calcium phosphate/lactose 75:25, with ·starch being added prior to compaction of the system 
VI 
N 
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A one-half percent concentration of starch, however, was not 
effective in reducing the disintegration time to under two hours. 
Concentrations of one and two percent yielded adequate disintegration 
times; and these times differed from those of the previous system. 
This result may have been due to some intra-, and extragranular 
disintegrant aiding both the disintegration and aggregation phenomena. 
However, by adding an intragranular disintegrant, there was no 
appreciable advantage over mixing of each ingredient separately. In 
fact, the disintegration process was more efficient when the tablet 
formulation was prepared by the latter method. 
The sum effect of processing procedures on the disintegration 
process for the described pre-compression systems is illustrated in 
Fig. 9. 
Also, as noted previously, there was no significant change in 
hardness as the starch concentration increased. 
H. Evaluation of Low Levels of Tablet Disintegrants (Tables XIV-XXI): 
The data revealed that, while low level of tablet disintegrants 
have little effect on such parameters as tablet weight variation, 
thickness, and hardness, disintegration times were reduced 
significantly. In fact, even at concentrations as low as 0.25% (w/w), 
one disintegrant reduced disintegration time from greater than two 
hours, to just over one minutes; a hundred-fold increase in the rate 
of disintegration. At a concentration of one percent, seven of the 
disintegrants induced greater than a ten-fold decrease in disintegra-
tion time. One-half of the disintegrants reduced the disintegration 
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I Excipients Compacted Separately , Starch Added in Blender. 
D Excipients Compacted Together , Starch Added in Blender. 
I Excipient System and Starch All Compacted Together. 
mmr -
B mi IDTITII 
Control 1/2 3 1% 2% 5 3 10 3 
Corn Starch Level 
Fig. Change in Disintegration Time as Disintegrant Level 
and Method of Incorporation are Altered. 
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AMBERLITE IRP-88 CONCENTRATION PROFILE 
Granulation and Tablet Properties 
Disintegrant Concentration 
Parameter Control 0.25% 0 . 5% 1% 2% 
Flow: 
Linearity * 19.5 19.6 19.4 19.3 18.9 
Flow Rate 241 234 223 211 201 
(gm/sec) 
Tablet: 
Weight 402 405 405 403 407 (mg) 
R.S.D. 0.7 0.4 0.4 0.3 0.2 
Thickness 3.30 3.34 3.33 3.34 3.37 (mm) 
R.S.D. 0.8 0.4 0.4 0.4 0.4 
Hardness 8.8 8.7 8.8 8.6 8.9 (kg) 
R.S.D. 12.7 9.5 11. 7 10.5 11.5 
Disintegration 
Time (min) 120+ 22.8 8.3 2.7 0.4 
Range 16.2-29.3 5.3-11.2 2.8-3.5 0.3-0.5 
Applied 
Pressure (lbs)3600 3553 3588 3640 3603 
R.S.D. 1.9 1.7 2.1 1.7 1. 7 
* (r 
2 0 . 8) x 100, see Experimental section -
( 
( 
Parameter 
Flow: 
Linearity* 
Flow Rate 
(gm/sec) 
Tablet : 
Weight 
(mg) 
R.S.D. 
Thickness 
(mm) 
R.S.D. 
Hardness 
(kg) 
R.S.D. 
Disintegration 
Time (min) 
Range 
Applied 
Pressure (lbs) 
R.S.D. 
CLD CONCENTRATION PROFILE 
Granulation and Tablet Properties 
Disintegrant Concentrat i on 
Control 0.25% 0 . 5% 1% 
19.5 19.6 18.9 19.2 
241 234 226 212 
402 406 407 403 
0.7 0 . 5 0.4 0.4 
3.30 3.35 3.33 3. 32 
0.8 0.4 0.6 0 . 5 
8.8 8.8 9.0 8.9 
12. 7 12. 3 10.1 12.8 
120+ 1.2 0.8 0.3 
0.5-1.9 0.6-0.9 0.3-0.4 
3600 3544 3841 3740 
1.9 2.0 1.7 1.7 
* (r 2 0.8) x 100, see Experimental section -
56 
2% 
19.0 
204 
397 
1.0 
3.30 
0.8 
8.9 
11. 3 
0.3 
0.28-0.33 
3491 
3.7 
( 
( 
Parameter 
Flow : 
Linearity* 
Flow Rate 
(gm/sec) 
Tablet: 
Weight 
(mg) 
R.S.D. 
Thickness 
(mm) 
R.S.D. 
Hardness 
(kg) 
R.S.D. 
Disintegration 
Time (min) 
Range 
Applied 
Pressure (lbs) 
R.S.D. 
AC-DI-SOL CONCENTRATION PROFILE 
Granulation anm Tablet Properties 
Disintegrant Concentrat i on 
Control 0.25% 0.5% 1% 
19.5 19.5 19 . 6 19.2 
241 234 223 219 
402 402 405 402 
0.7 0.3 0.3 0.2 
3.30 3.27 3.29 3.28 
0.8 0.6 0.5 0.5 
8.8 9.9 9.7 9.1 
12.7 10.2 9.2 12 .1 
120+ 4.8 1.9 0.6 
3 . 1-5.5 0.9-2.1 0.5-0.7 
3600 3767 3783 3852 
1.9 1. 9 2.4 1 .5 
* ( r 2 0.8) x 100, see Experimental section -
57 
2% 
19.2 
211 
401 
0 . 3 
3.31 
0.4 
8.4 
12.2 
0.5 
0.4-0.5 
3662 
1.8 
( 
Parameter 
Flow: 
Linearity* 
Flow Rate 
(gm/sec) 
Tablet: 
Weight 
(mg) 
R.S.D. 
Thickness 
(mm) 
R.S.D. 
Hardness 
(kg) 
R.S.D. 
Disintegration 
Time (min) 
Range 
Applied 
Pressure (lbs) 
R.S.D. 
EXPLOTAB CONCENTRATION PROFILE 
Granulation and Tablet Properties 
Disintegrant Concentration 
Control 0 . 25% 0.5% 1% 
19.5 19.4 19.6 19.4 
241 233 228 222 
402 399 401 398 
0.7 0.3 0.4 0.5 
3.30 3.26 3.29 3.27 
0.8 0.5 0.·7 0.6 
8.8 9.6 9.1 10.1 
12.7 14.1 14.4 9.6 
120+ 14.5 4.6 2.6 
9. 8-11. 2 3.2-6.1 2.1-3.0 
3600 3821 3693 3768 
1.9 1.4 1.4 1.6 
* (r 2 0.8) x 100, see Experimental section -
58 
2% 
19.5 
217 
400 
0.3 
3.32 
0.5 
8.2 
10.4 
1. 0 
0. 9-1. 3 
3595 
1. 7 
( 
( 
Parameter 
Flow: 
Linearity* 
Flow Rate 
(gm/sec) 
Tablet: 
Weight 
(mg) 
R.S.D. 
Thickness 
(mm) 
R.S.D. 
Hardness 
(kg) 
R.S.D. 
Disintegration 
Time (min) 
Range 
Applied 
POLYPLASDONE XL CONCENTRATION PROFILE 
Granulation and Tablet Properties 
Disintegrant Concentrat i on 
Control 0 . 25% 0 . 5% 1% 
19.5 
241 
402 
0.7 
3.30 
0.8 
8.8 
12.7 
120+ 
19.4 
244 
406 
0.3 
3.34 
0.4 
8.8 
12.0 
17.8 
19.4 
240 
403 
0.5 
3.30 
0.6 
9.0 
15.2 
6.5 
1 9 . 6 
232 
396 
1. 5 
3.29 
0.6 
7.7 
17.6 
2.7 
17.2-18.4 5.2-7.8 1.4-3.9 
Pressure (lbs) 3600 3676 3729 3594 
R.S.D. 1.9 2.3 5.7 5.2 
* (r2 - 0.8) x 100, see Experimental section 
59 
2% 
19.5 
219 
388 
1.0 
3.24 
0.6 
8.4 
5.7 
0.4 
0.38-0.42 
3543 
5.0 
( 
( 
CORN STARCH U.S.P. CONCENTRATION PROFILE 
Parameter 
Flow: 
Linearity* 
Flow Rate 
(gm/sec) 
Tablet: 
Weight 
(mg) 
R.S.D. 
Thickness 
(mm) 
R.S.D. 
Hardness 
(kg) 
R.S.D. 
Disintegration 
Time (min) 
Range 
Applied 
Pressure (lbs) 
R.S.D. 
Granulation and Tablet Properties 
Disintegrant Concentration 
Control 0.25% 0 . 5% 1% 
19.5 19.3 19.4 19.2 
241 238 227 212 
402 403 403 404 
0.7 0.3 0.4 0.4 
3.30 3.31 3.31 3.30 
0.8 0.4 0.4 0.5 
8.8 8.5 8.4 9.1 
12.7 7.3 9.8 11. 2 
120+ 55.8 54.2 16.5 
28.6-63.2 38.0-70.4 12.2-20.8 
3600 3557 3735 3826 
1.9 1. 6 2.3 1.7 
* (r 2 0.8) x 100, see Experimental section -
60 
2% 
19.1 
206 
404 
0.6 
3.33 
0.7 
8.6 
10.5 
12.0 
10.2-13.8 
3590 
2.2 
( 
STA-RX 1500 STARCH CONCENTRATION PROFILE 
Parameter 
Flow: 
Linearity* 
Flow Rate 
(gm/sec) 
Tablet: 
Weight 
(mg) 
R.S.D. 
Thickness 
(mm) 
R.S.D. 
Hardness 
(kg) 
R.S.D. 
Disintegration 
Time (min) 
Range 
Applied 
Pressure (lbs) 
R.S.D. 
2 
Granulation and Tablet Properties 
Disintegrant Concentration 
Control 0.25% 0.5% 1% 
19.5 19.4 19.6 19.2 
241 231 220 212 
402 410 411 405 
0.7 0.4 0.4 0.5 
3.30 3.36 3.36 3.28 
0.8 0.7 0.6 0.6 
8.8 8.3 8.8 10.5 
12.7 9.9 11.4 8.6 
120+ 34.5 21.3 10.3 
31. 6-53. 5 18.6-34.0 8.8-11.8 
3600 3636 3745 4092 
1.9 1. 6 1.6 5.6 
* (r - 0.8) x 100, see Experimental section 
61 
2% 
19.1 
201 
411 
0.5 
3.39 
0.6 
7.9 
11. 7 
5.8 
3.8-7.8 
3512 
2.5 
( 
Parameter 
Flow: 
* Linearity 
Flow Rate 
(gm/sec) 
Tablet: 
Weight 
(mg) 
R. S.D. 
Thickness 
(mm) 
R.S.D. 
Hardness 
(kg) 
R.S.D. 
Disintegration 
Time (min) 
Range 
Applied 
Pressure (lbs) 
R.S.D. 
GUAR GUM CONCENTRATION PROFILE 
Granulation and Tablet Properties 
Disintegrant Concentration 
Control 0.25% 0 . 5% 1% 
19.5 19.2 19 . 4 18.9 
241 238 233 218 
402 405 404 409 
0.7 0.5 0.7 0.6 
3.30 3.33 3.33 3.35 
0.8 0 . 7 0.7 0.7 
8.8 8.2 8.1 8.6 
12.7 15.6 12.9 13.4 
120+ 9.7 7.5 3.4 
7.3-12.2 4.3-10.7 2.7-4.1 
3600 3571 3668 3754 
1.9 3.7 3.3 1. 7 
* 
(r 2 0.8) x 100, see Exp~riment al sect ion -
62 
2% 
_18.9 
196 
409 
0.4 
3.36 
0.5 
8.7 
10.9 
2.2 
1. 8-2. 7 
3714 
3.3 
( 
( 
time to under one minute at a concentration of two percent, an 
acceptable value for almost any formulation. 
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Changes in powder flow were not significant for low levels of 
disintegrant, although there might have been a general decreasing 
trend in linearity of the flowgram with increases in concentration 
of disintegrant. The mass flow rate of the powder, in all cases, 
decreased with increasing disintegrant concentration, although only 
low levels of disintegrant were used. 
Examination of the disintegration times on Tables XIV-XXI, made 
possible the selection of five disintegrants that were effective in 
effecting tablet disintegration in one minute or less. The effect of 
these substances on other parameters such as weight, thickness, 
hardness and weight variation was not significant; and thu~ on the 
basis of availability of various particle sizes, and powder flow 
characteristics, polyvinylpolypyrrolidone (P.V.P.P.) was selected for 
further study and subsequently optimization. It should be stressed 
that any of a number of other disintegrants could have been chosen 
for this stage of the study and that this choice is somewhat 
subjective. Further, it was thought that a detailed study of a single 
agent would be more beneficial than a superficial study of a number of 
disintegrants. 
Since three particle size ranges of P.V.P.P. were available 
(0-15 microns, 50-100 microns, 50-300 microns), a study of the effect 
of particle size on disintegrating efficiency was undertaken. In 
addition, since tablet porosity seemed to affect disintegration, 
( 64 
three excipients with varying densities, particle sizes, and inherent 
porosity when tableted were chosen. These excipients were calcium 
phosphate (Emcompress) and two particle size ranges of microcrystalline 
cellulose (Avicel PHlOl, PH102). The three particle size ranges of 
P.V.P.P. were designated as "A" (0-15 microns), "B" (50-100 microns) 
and "C" (50-300 microns) . 
I. Evaluation of the Three Grades of P.V.P.P. (Tables XXII-XXV): 
Table XXII shows the flow characteristics of the three grades 
of P. V .P .P. in the three excipient systems. For each excipient the 
trend seemed similar: as particle size increased and broadened, 
flow tended to improve, although this observation was more apparent 
with the faster flowing excipient (Emcompress) than the slower ones 
(Avicels). 
The aspirin formulation described earlier in part E of the 
methodology section (30% A.S.A., 2% P.V.P.P.) was prepared for the 
three grades of P.V.P.P. in the three excipients. The formulations 
were compressed on a rotary tablet press, with constant die fill, 
and tablets were tested by methods described earlier. The results 
of these tests were compiled and listed in Tables XXIII-XXV. 
The R.S .D. values corresponding to tablet weights seemed well 
within acceptable limits. Changes in tablet weights were probably due 
to the differing densities of the P.V.P.P. grades and the matrices. 
With the more-dense matrix (Emcompress), as P.V.P.P. particle size 
increased, there was a trend to decrease tablet weight given the same 
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FLOW PROPERTIES OF. THREE MATRICES .. CONTAINING 
2% (W/W) P.V.P.P. IN THREE PARTICLE SIZE RANGES. 
GRADE OF P.V.P.P. 
EMCOMPRESS: A B c 
Mass Flow1 163 194 224 
L . · t 2 1near1 y 17.9 18 . 8 18.4 
AVICEL PH-101: 
Mass Flow 1 22 22 24 
Linearity2 18.1 18.4 19.1 
AVICEL PH-102: 
Mass Flow 1 29 29 30 
L. ' t 2 1near1 y 17.7 17.9 18.6 
1. mean gram/second rate for 3 trials 
2. mean (r2-0.8) x 100 value for 3 trials 
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PROPERI'IFS OF TABI.EI'S MADE wrrn 30% A. S. A. IN 
:EM:X:MPRESS AND 2% P.V.P.P. IN THREE PARTICLE SIZE RANGES 
Pa:rticle. Size Grade 
A B c 
- -
WEIGHT (~) 403 382 377 
R.S.D. o. 0.9 1.2 
THICKNESS (rrm) 4.3 4 . 3 4.2 
R.S.D. 0.6 0.5 0.6 
HARDNESS (kg) 5.8 5.3 4.8 
R.S.D. 8.1 15.5 14.1 
DISINIEGRATION (sec) 71 58 34 
RANGE 45-79 30-70 30-40 
FRIABILITY (%) 0.7 0.8 0.9 
{ 
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PROPERI'IFS OF TABI.EIS MADE WITH ~ A.S.A. IN 
AVICEL PH-101 AND 2% P.V.P.P. IN THREE PARrICLE SIZE RANGE'S 
Particle Size Grade 
A B c 
-
WEIGHT (Ill;) 276 284 292 
R.S.D. 1.9 1.4 0.5 
THICKNESS (rrm) 3.8 4.0 4.0 
R.S.D. 1.6 0.8 0.7 
HARDNESS 8.6 6.8 6.4 
R.S.D. 13.7 20.4 9.9 
c DISINI'EGRATION (sec) 47 33 46 
RANGE 30-70 25-40 30-60 
FRIABILITY (%) 0.4 0.6 0.7 
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PROPERTIFB OF TABLETS MADE WITH 30}h A.S.A. IN 
AVICEL PH-102 AND Z'/o P.V.P.P. IN THREE PARTICLE SIZE RANGES 
Particle Size Grade 
A B c 
-
WEIGHI' (~) 295 296 300 
R.S.D. 1.3 1.9 0.8 
THICKNESS (mn) 4.0 4.1 4.2 
R.S.D. 0.8 1.6 0.9 
HARDNESS (kg) 6.5 6.3 6.0 
( R.S.D. 14.4 12. 7 6.9 
DISINIEGRATION (sec) 47 47 44 
RANGE 40-55 40-55 43-46 
FRIABILI'IY (%) 0.2 0.3 0.4 
( 
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die-fill. With the less-dense matrices (Avicels), this trend seemed 
to be reversed. 
With respect to tablet thickness, the trend was similar to that 
of tablet weight, also probably due to density properties. 
The tablet hardness showed a trend to decrease as particle size 
increased. However, this trend did not seem to be dramatic. 
In almost all cases, the disintegration times were below one 
minute and for an aspirin tablet, this ti.me seemed satisfactory. 
However, out of the three grades, the broadest particle size range, 
"C", gave the quickest disintegration. 
There was also a slight trend to increase the percent friability 
as particle size increased for the P.V.P.P. However, the trend to 
increase the amount of compact lost due to .abrasion was slight and 
was well below acceptable limits (workers at U.R.I. have generally 
recognized two percent friability as the cut-off point). 
Tablet dissolution data was corrected for experimental error and 
plotted in Fig. 10-12. In all cases, the grade of P.V.P.P. that 
achieved the fastest and greatest dissolution of drug had the largest 
particle size range, range C. This effect was best seen in Fig. 12 
where Emcompress was used as the matrix. 
These data led to the selection of particle size grade C for 
further study. 
J. Determination of an Effective Concentration of Grade C (Fig. 12-17, 
Table XXVI): 
In the multivitamin formulation described earlier, the percent 
P.V.P.P . (grade C) was increased gradually to twenty percent (w/w). 
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Fig. -Aspirin Dissolution Curves for the Three Grades of P.V.P.P. used 
in the Eioccmpress Formulation ( 30% A. S. A. , 2% P. V .P. P. ) . 
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Fig. -Aspirin Dissolution Curves for the Three Grades of P. V .P .P. used 
in the Avicel PH-101 Fornrulation (3~ A.S.A., Zfo P.V.P.P. ). 
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Fig. -Aspirin Dissolution Curves for the Three Grades of P. V .P .P. used 
in the Avicel PH-102 Fonnul.ation (30% A.S.A., 2% P.V.P.P.). 
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Fig. 12 represents the change in mean tablet weight as the P.V.P.P. 
concentration increased. The weight generally decreased as the 
concentration increased, although there was a slight increase in 
tablet weight at the one percent level. This result may have come 
from the small amount of P.V.P.P. acting as a flow aid, allowing more 
powder to fill the die. 
Tablet thickness (Fig. 13) also increased at the one percent 
level and then decreased gradually. This may again be due to the small 
amount of P.V.P.P. acting as a flow aid. The thickness tended to 
increase at high levels of P.V.P.P. and this may have been caused by 
absorption of water. Table XXVI lists the flow properties of the 
P.V.P.P. and it can be seen that the flow did increase slightly at 
the one percent level and thus the flow aid theory may have some 
validity. The mass flow rate decreased with increasing P.V.P.P. 
concentration, although the linearity was minimally affected. This 
decrease may have been due to the fast flowing excipient (Emcompress). 
It is suggested that a matrix with a slower flow rate would show more 
of a change in linearity than mass flow. 
Fig. 14 illustrates the noticeable decrease in tablet hardness as 
P.V.P.P. concentration increased. This trend is mirrored in Fig. 15, 
the change in tablet friability as P.V.P.P. concentration increases. 
The amount of tablet lost due to abrasion increased as P.V.P.P. 
concentration increased. From the latter graph, it is obvious that a 
concentration above six percent would yield unacceptable friability 
values. 
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Fig. -change in Tablet Weight as Percent P. V. P. P. Increases 
in a Multivitamin Formulation. 
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Fig. -Change in Tablet 'Ib.ickness as Percent P.V.P.P. Increases 
in a Multivitamin Forrrulation. 
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EFFECT OF INCREASING AMOUNTS OF P.V.P.P.("C") 
ON FLOW PROPERTIES OF EMCOMPRESS 
% P.V.P.P. FLOW RATE 1 LINEARITY2 
Control 227 18.6 
1 
2 
5 
10 
20 
1. 
2. 
227 
203 
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177 
131 
mean gram/second rate for 3 trials 
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Fig. -Change in Tablet Hardness as Percent P.V.P.P. Increases 
in a Multivitamin Fonnulation. 
20 
78 
20-
maximum acce table limit 
0 4 8 
Percent P.V.P.P. 
Fig. -Change in Friability as Percent P.V.P.P. Increases 
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Fig. 16 shows the change in tablet disintegration as P.V.P.P. 
concentration increased. As expected, the disintegration time 
decreased as P.V.P.P. concentration increased. The effect of P.V.P.P. 
on reducing disintegration time seems to be limited after about five 
percent. Thus it seems that there would be little use in adding 
P.V.P.P. in concentrations above five percent; and in fact, such a 
course of action would increase the likelihood of adverse complications 
in tablet performance. 
Fig. 17 shows dissolution curves for two levels of P.V.P.P. in the 
aspirin formulation described earlier. As one would expect, as 
percent P.V.P.P. increased from two to four percent, the dissolution 
rate increased. The extent of drug dissolution was not affected. 
Fig. 18 shows three replicate dissolution curves for the aspirin 
formulation; and as one can see, there was some variation between 
the three trials. However, this variation was not very great, and 
could be considered normal for dissolution of drugs. The time for 
90% of the drug to be in solution for all three trials varied only 
by about three minutes. 
Table XXVII lists tablet data for the pyridoxine formulation 
described in part E of the methodology section. The tablet weight 
variation, content (assayed), and friability were all within 
acceptable limits. The disintegration time was very fast, and con-
sidering all factors, this fi.ormulation performed very well when 
tableted. Fig. 19 shows three replicate dissolution curves for 
pyridoxine in this formulation. In all cases, the dissolution rate 
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Fig. -Change in Disintegration Time as Percent P.V.P.P. Increases 
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Fig. -Dissolution Curves for Two Levels of Grade "C" P.V.P.P. 
Used in an Aspirin/Emcompress Formulation (30% A.S.A.). 
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Fig. -Three Replicate Dissolution Curves for the Aspirin/Elncanpress 
Formulation Tablets (3atb A.S.A., 2% Grade C P.V.P.P.). 
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TABLET DATA FOR PYRIDOXINE (B6) FORMULATION 
MEAN R.S.D. 
WEIGHT (mg.) 1 100.6 1.7 
THICKNESS (mm. ) 1 2.50 0.8 
DISINTEGRATION (sec.) 2 8 6-10 (Range) 
FRIABILITY (%) 3 0.8 
4 5.03 0.02 CONTENT (Assayed) mg. 
1. n=lO 
2. n=6 
3. n=20 
4. n=30 
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was extremely fast, and all three trials produced a 90% dissolution 
time below three minutes. 
( 
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GENERAL CONCLUSIONS AND SUGGESTIONS FOR FURTHER WORK 
In general, when a formulator processes a formulation on a piece 
of equipment, he must understand the limitations of that apparatus. 
With such knowledge, he will be able to select machines, or methods, 
to achieve optimum efficiency of his process variables with regard 
to the formulation of the pharmaceutical dosage. Since pre-compression 
as a granulation process (using a chilsonator/mill or by slugging/ 
milling) is more and more desirable for processing of water-sensitive 
drugs, a complete understanding of such equipment is necessary. 
When the chilsonator /mill was used in this study, a computerized 
regression showed that the speed of the compression rollers, which 
altered the time that the powder was exposed to compression was the 
most important factor in the increase in particle size of the granula-
tion. The next most important parameter was the rate of feed of 
powder flow into the compression rollers. Surprisingly, the compres-
sional force between the rollers was the least significant factor. 
The method of incorporation of a mixture of water-soluble and 
water-insoluble excipients made little difference on disintegration 
time and other physical properties of tablets. However, when a 
complex pre-compression system, that contained a disintegrant, was 
produced by various methods, the disintegration times and hardness 
86 
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of the tablets varied significantly. From this study, it seemed 
evident that the best method of incorporation of a disintegrant into 
a tablet granulation would be: first, compact the water soluble 
ingredients together; second, compact the insoluble ingredients 
together; and finally, add the disintegrant to these granules in a 
blender 1 without any compaction. This process is very close to that 
which many people refer to as "direct compression." Since many of the 
direct compression excipients marketed today are made by compaction, 
this finding was not altogether unexpected. Future work could usefully 
focus on compacting various water soluble and water insoluble drugs 
with various excipients to determine whether or not solubility of 
excipients would be an important factor in drug release rate from 
pre-compressed systems. Other investigations could perhaps address 
tablet and granule porosity changes that occur with various methods of 
incorporation of both drugs and disintegrants. 
The present study has shown conclusively that there are some 
properties of a pharmaceutical formulation that are adversely affected 
by large amounts of tablet disintegrants. The problems that can occur, 
such as poor powder flow, reduced tablet hardness and increased tablet 
friability, may be avoided by using low concentrations of tablet 
disintegrants. A number of disintegrants, thought to be effective at 
concentrations of five percent or greater, have been shown to induce 
disintegration of tablets are concentrations as low as one or two 
percent. Another possible topic for future research might be the study 
of the effects of low concentrations of disintegrants in wet granulation 
systems. 
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When relative disintegrating efficiency has been established and 
one specific tablet disintegrant has been chosen, the formulator 
should not stop the optimization process there. The work reported 
in this thesis has shown that altering particle size. of a tablet 
disintegrant can effect great changes in disintegration time as well 
as both the rate and extent of drug dissolution. Other properties 
such as powder flow, tablet hardness and tablet friability were also 
affected by such changes and thus should be considered. In this 
connection, another area which would merit further study would be 
the evaluation of the effect of varying particle size of other 
disintegrants. Further, it would be interesting to study a wider 
range of drugs and their subsequent release from tablets made with 
these disintegrants. 
Although it may seem that the selection of a formulation containing 
a specific tablet disintegrant is an extremely long, drawn-out 
process, it does not necessarily have to be that way. Knowing the 
advantages and the limitations of the variou processes and equipment 
available to the formulator, he can make many reasonable assumptions 
based on this information, and eliminate many of the preliminary 
evaluation steps. This study has tried to shed light on some of the 
evaluation processes and limitations associated with them. When one 
selects any tablet disintegrant, he should strive to optimize all 
aspects of the disintegrant in the given pharmaceutical formulation. 
He may achieve this end by altering method of incorporation, particle 
size, excipient solubility, compression force, disintegrant concentra-
tion and other factors. 
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Every pharmaceutical system is unique, and the optimization 
process must therefore be unique to any given system. Certain 
procedures that will apply for one system may not be applicable to 
another. Although a study of all of these procedures and applications 
would be overwhelming, the results reported in this thesis show that a 
rational approach to formulation is indeed practicable. The traditional 
intuitive approach which is still so widely used in the formulation of 
pharmaceutical products can in many areas of tablet formulation and 
processing quite properly be regarded as obsolescent. It is hoped that 
with an understanding of the disintegration process and the variables 
which affect it, optimization of a tablet disintegrant in a given 
pharmaceutical system will become increasingly common within the 
pharmaceutical industry. 
( 
( 
( 
REFERENCES 
1. J.M. Richards, U. S. Patent #216,107 (1879). 
2. · W. Lowenthal, J. Phann. Sci., 61: 1695 (1972). 
3. J. Cooper, J. E. Rees, J. Phann. Sci., 61: 1511 (1972). 
4. R. R. Levine, "Phannacology: Drug Actions and Reactions," 1st 
Edition, Little, Brown and Co., 1973, p. 83. 
5. J. K. Halebian, F. W. Goodhart, J. Pharm. Sci., 64: 1085 (1976). 
6. W. C. Gunsel, J. L. Kanig, in "The Theory and Practice of 
Industrial Phannacy," 2nd Edition, Lea and Febiger, 1976, 
Philadelphia p. 297. 
7. K. Marshall, in "Modern Phannaceutics" (G. S. Banker and C. T. 
Rhodes, Eds.), Marcel Decker, Inc., 1979, New York pp. 336-408. 
8. E. L. Parrott, "Phannaceutical Technology," Burgess Publishing 
Co., 1970, Minneapolis, p. 82. 
9. H. C. Ansel, "Introduction to Pharmaceutical Dosage Forms," Lea 
and Febiger, 1972, Philadelphia, p. 297. 
10. "The National Formulary," XIV Edition, Mack Publishing Co., 
Easton, Pennsylvania, 1975, p. 941. 
11. N. R. Bohidar, F. A. Restaino, and J. B. Schwartz, J. Phann. Sci., 
64: 966 (1975). 
12. B. Hoener and L. Z. Benet, in "Modern Pharmaceutics," (G. S. 
Banker and C. T. Rhodes, Eds.), Marcel Decker, Inc., 1979, 
New York, pp. 158-162. 
90 
( 
( 
13. 
14. 
15. 
16. 
17. 
18. 
19. 
20. 
21. 
91 
J.B. Schwartz, Ibid., pp. 711-734. 
K. Marshall, D. Sixsmith, Drug Develop. Comm., 1: 51 (1974). 
F. Fuchs, Arch. Pharm., 303: 471 (1970). 
K. A. Kahn, C. T. Rhodes, J. Pharm. Pharmacol., 23: 261A (1971). 
W. Feinstein, J. Bartilucci, J. Pharm. Sci., 55: 331 (1966). 
W. Lowenthal, J. A. Wood, Ibid., 62: 287 (1973). 
R. Huttenrauch, Pharmazie, 26: 293 (1971). 
A. M. Khalek, A. A. Kader, J. Pharm. Sci., UAR 5: 114 (1964). 
E. E. Bozunov, S. M. Shevchenko, Farmatisya (Moskow), 18: 20 
(1969), through Chem. Abstr. 71: 33385y (1969). 
22. N. R. Patel, R. E. Hopponen, J. Pharm. Sci., 55: 1065 (1966). 
23. H. Matsumaru, Yakigaku Zasshi, 78: 1198 (1958), through Chem. 
Abstr., ~3: 3602a (1959). 
24. L. Krowczynski, K. Kolarski, and K. Swoboda, Acta. Pol. Pharm., 
25: 443 (1968). 
25. F. Jaminet, L. Delattre, and G. Godfriaux, J. Pharm. Belg., 
22: 95 (1967). 
26. H. V. Czetsch-Lindenwald, F. El Khawes, and R. Tawashi, J. Soc. 
Cosmet. Chem., 16: 251 (1965). 
27. N. J. Van Abbe and J. T. Rees, J. Amer. Pharm. Assoc., Sci. Ed., 
47: 487 (1958). 
28. W. J. Husa, Ibid., 17: 38 (1928). 
29. I. K. McKee .and W. Herbst (to National Starch and Chemical Corp.), 
U. S. Patent #3,034,911 (1962). 
30. F . Jaminet, J. Phann. Belg., 19: 144 (1964). 
( 92 
31. H. Berry and C. Ridout, J. Pharm. Pharmacol., 2: 619 (1950). 
32. M. H. Rubinstein, D. M. Bodey, J. Pharm. Pharmacol., 26: 104P 
(1974). 
33. E. Shotten, G. S. Leonard, Ibid., 24: 798 (1972). 
34. K. A. Kahn, D. I. Rooke, Manuf. Chemist & Aerosol News, I (1976). 
35. J. B.Schwartz, E.T. Martin, and E. J. Dehner, J. Pharm. Sci., 
64: 966 (1975). 
36. N. R. Bohidar, F. A. Restaino, and J. B. Schwartz, J. Pharm. Sci., 
64: 966 (1975). 
37. "Problem Solver," FMC Corporation, Philadelphia, pp. III-10. 
38. W. Lowenthal, J. Pharm. Sci., 61: 1705 (1972). 
39. J.B. Schwartz, J. R. Flamholz, R. H. Press, J. Pharm. Sci., 
62: 1165 (1973). 
40. Ibid., 62: 1518 (1973). 
41. N. R. Bohidar, F. A. Restaino and J.B. Schwartz, Drug Develop. 
and Indust. Phann., 5(2), 175 (1979). 
42. S. S. Kornblum, S. B. Stoopack, J. Pharm. Sci., 62: I (1972) . 
43. A. M. Sakr, A. A. Kassem, Mfg. Chem., Aerosol News, 43: 37 (1972). 
44. J. B. Schwartz and J. A. Zelinskie, Drug Develop. and Indust. 
Pharm., 4(5), 463 (1978). 
45.. W. C. Gunsel and J. L. Kanig, in "The Theory and Practice of 
Industrial Pharmacy," 2nd Edition, Lea and Febiger, 1976, 
Philadelphia, pp. 336, 337. 
46. H. K. Malinowski, Ph.D. Dissertation, Philadelphia College of 
Pharmacy, 1973. 
( 
( 
( 
93 
47. K. Marshall, in "Hodern Pharmaceutics," (G. S. Banker and C. T. 
Rhodes, Eds.) Marcel Decker, Inc., New York, 1979, p. 399. 
48. H. Kavarana and H. M. Burlage, Amer. Prof. Pharm., 21, 348, 383, 
450, 473 (1955). 
49. T. Higuchi, A. N. Rao, L. W. Busse, and J. V. Swintosky, J. Amer. 
Pharm. Assoc., Sci. Ed., 42, 194 (1953). 
50. E. P. Stevens and J. W. Wallace, in "Problem Solver," FMC 
Corporation, Philadelphia, 1977. 
51. H. Sprengler and J. Jud, Pharm. Acta. Helv., 12, 337 (1937). 
52. K. Kolarski and L. Krowczynski, Acta. Pol. Pharm., 27, 477 (1970). 
53. V. C. Krebs, An. Fae. Quim. Farm., Univ. Chile, 11, 204 (1959), 
through Chem. Abstr., 54, 25575f (1960). 
54. J. T. Ingram and W. Lowenthal, J. Pharm. Sci., 55, 614 (1966). 
55. A. D. Nair and V. N. Bhatia, J. Amer. Pharm. Assoc., Sci. Ed., 
46, 131 (1957). 
56. H. Burlinson and C. Pickering, J. Phann. Pharmacol., 2, 630 (1950). 
57. H. M. Gross and C.H. Becker, J. Amer. Pharm. Assoc., Sci. Ed., 
41, 157 (1952). 
58. H. Gibian, et al., Acta Physiologica Latinoamericana, 18, 323 
(1968). 
59. J. G. Reinhold, et al., Amer. Jour. Med. Sci., 210, 141 (1945). 
60. J. G. Wagner in "Biopharmaceutics: Gastrointestinal Absorption 
As pee ts," Pharmaco kinetic u. Arznei.mit t eldo sierung , Ko llo qu ium, 
Borstel, 1962. 
61. A. J. Glasko, et al., Clinical Pharmacy and Therapeutics, 9, 472 
(1967). 
( 
62. 
94 
K. Kakerni, et al., Symposium on Drug Absorption, Metabolism and 
Excretion, Paper B-IV, Preprints of Papers (Scientific .Section 
of the American Pharmaceutical Association), Las Vegas, (1962). 
63. R. R. Levine and E.W. Pelikan, Annu. Rev. Pharmacol., 4: 69 
(1964). 
64. The American Heritage Dictionary, William Morris, Ed., Dell 
Publishing Co., Inc., New York, 1979. 
65. Remington's Pharmaceutical Sciences, 15th Edition, Mack 
Publishing Co., Easton, Pennsylvania. 
66. Sprowls American Pharmacy, 7th Edition, 1974, J.B. Lippincott 
Co., Philadelphia. 
67. W. G. Gunsel and J. L. Kanig in "The Theory and Practice of 
( Industrial Pharmacy," 2nd Edition, 1976, Lea and Febiger, 
Philadelphia. 
68. H. A. Berry and C. W. Ridout, J. Pharm. Pharmacol., 2, 619 (1950). 
69. R. A. Ramsay, Ibid., 10, 145t (1958). 
70. H. Nogami, J. Hasegowa, M. Miyamoto, Chern. Pharm. Bull., 57, 279 
(1967). 
71. W. Lowenthal, R. A. Buruss, J. Pharm. Sci., 60, 1325 (1971). 
72 .. E. L. Knoechel, C. C. Sperry, and C. J. Lintner, J. Pharm. Sci., 
56, 116 (1967). 
73. T. Higuchi, L. N. Elowe, L. W. Busse, J. Amer. Phann. Assoc., 
Sci. Ed., 43, 685 (1954). 
74. J. B. Schwartz, in "Modern Pharmaceutics," (G. S. Banker and C. T. 
Rhodes, Eds.), Marcel Decker, Inc., New York, 197.9. 
75. K. Marshall, in "The Physics of Tablet Compression," Presented 
at the 12th Annual Arden House Conference, Feb. 2, 1977. 
( 
( 
95 
76. H. Sprengler and E. Shenker, Pharm. Acta. Helv., 12, 337 (1937). 
77. H. Sprengler and J. Jud, Ibid., 18' 565 (1943) . 
78. w. Feinstein and A. J. Bart illucci, J. Phann. Sci., 55' 332 (1966). 
79. T. A. Fakouki, N. F. Billups and R. w. Sager, J. Phann. Sci., 
52' 700 (1963) . 
80. H. DeLonca, A. Puech, M. DeLonca and N. V. Doi, J. Phann. Belg., 
21, 67 (1966). 
81. E. M. Rudnic, R. Chilamkurti, and C. T. Rhodes, Drug Develop. 
and Indust. Phann., May (3), (1980). 
82. E. H. Rudnic, R. Chilamkurti, and C. T. Rhodes, Ibid., May (3), 
(1980). 
83. N. R. Patel, R. E. Hopponen, J. Phann. Sci., 55, 1065 (1966). 
84. D. E. Cadwallader, in 11Biophannaceutics and Drug Interactions, 11 
2nd Edition, Rocom Press, New Jersey, 1974, pp. 58-64. 
85. The National Formulary, XIV Edition, Mack Publishing Co., Easton, 
Pennsylvania, 1975, p. 978. 
86. L. L. Kaplan, J. Pharm. Sci., 53, 447 (1964). 
87. G. Gold, R. N. Duvall, B. T. Palermo, J. Phann. Sci., 57, 667 
(1968) ·. 
88. R. N. Duvall, in ''Methods of Evaluating and Factors Affecting 
the flow of Pharmaceutical Powers, 11 Presented at the Regional 
!PT Meeting, Academy of Pharmaceutical Sciences, Philadelphia, 
Pennsylvania, October 16, 1970. 
89. R. P. Jordan, C. T. Rhodes, Drug Develop. and Indust. Phann., 
5, 151 (1979). 
( 
( 
( 
90. M. J. Stokosa, "Pharmaceutical Calculations," 6th Edition, 
Lea and Febiger, Philadelphia, 1974. 
96 
91. G. L. Jenkins, A. M. Knevel, and F. E. DiGangi, "Quantitative 
Pharmaceutical Chemistry," 6th Edition, McGraw-Hill Book Co., 
New York, 1967. 
92. S. C. Choi, "Introductory Applied Statistics in Science," 
Prentice Hall Co., New Jersey, 1978. 
93. G. W. Snedecor and W. G. Cochran, "Statistical Methods," 6th 
Edition, Iowa State University Press, Ames, Iowa, 1978. 
94. Lange's Handbook of Chemistry, N. A. Lange, Ed., Revised 10th 
Edition, McGraw-Hill Book Co., New York, 1969. 
95. R. T. Morrison and R. N. Boyd, "Organic Chemistry," 3rd Edition, 
Allyn and Bacon, Inc., Boston, 1973. 
96. Handbook of Chemistry and Physics (R. C. Weast, Editor), 52nd 
Edition, Chemical Rubber Co., Cleveland, Ohio, 1972. 
97. The Unit·ed States Pharmacopeia, XIX, United States Pharmacopeia 
Convention, Rockville, Maryland, 1975. 
